Anti-Bacterial Drugs Market was Valued at US$ 43,444.9 million and is Anticipated to Grow to US$ 49,871.0 million by 2019 at a CAGR of 3.1%

The Anti-Bacterial segment includes few of the oldest classes of drugs that have enriched the industry over past several decades. With over 80% of the total market share being held by generics, the major brands hold a small percentage of shares in the market. In 2014, the global anti-bacterial drugs market was valued at US$ 43,444.9 million and is anticipated to grow to US$ 49,871.0 million by 2019 at a CAGR of 3.1%. Over the past two decades, there has been a significant rise of drug resistance among humans. MRSA and other drug resistant superbugs and microbes have always been a challenge for the pharmaceutical companies. In the face of rising incidence of hospital and community acquired bacterial diseases, the market for antibacterials as a whole is expected to benefit. As compared to the last decade, companies such as Cubist and Cempra are leading the way in introducing anti-bacterials posed to combat the challenges of drug resistant super bugs. At least 39 anti-bacterial compounds are undergoing clinical trials across a variety of classes, with 25 of these in phase 2 or 3 clinical trials, and 3 compounds under review at the FDA. There had been no new classes of anti-bacterial drugs for almost thirty years, however a latest article researchers have discovered a new drug, called teixobactin, which marks the launch of a new class of antibiotics.

Market Drivers:
Increasing incidence of hospital and community acquired bacterial infections pushing growth of brands and generics Improving
Legal Framework for provision of Incentives expected to drive growth

Market Inhibitors:
Limited pipeline drugs and absence of new indication targets may lead to significant erosion against generics

Free Sample Report@ http://www.sa-brc.com/Global-Anti-Bacterial-Drugs-Market-Assessment--Forecast-2015-2019/sample2

Current Drugs Covered In This Report:

Cubicin
Teflaro/Zinforo
Dificid
Dalvance
Orbactiv
Sivextro
Zerbaxa
Avycaz
Zyvox
Avelox
Augmentin
Zosyn/Tazocin
Invanz
Tygacil

Pipeline Drugs Covered In This Report:
Surotomycin
Solithromycin
Delafloxacin
Plazomycin
Taksta
Cadazolid
Carbavance
Eravacycline

Click For Full Report@ http://www.sa-brc.com/report/Global-Anti-Bacterial-Drugs-Market-Assessment--Forecast-2015-2019/2

Key Players Covered In This Report:
Actavis Pharmaceuticals
Astrazeneca
Cempra Pharmaceuticals
Cubist Pharmaceuticals
Durata Therapeutics
Forest Laboratories
GlaxoSmithKline (GSK)
Johnson & Johnson (Janssen Pharma)
Melinta Merck & Co

About Us
Spearhead Acuity Business Research & Consulting Private Limited (SA-BRC) is a premium Life Science business intelligence and data analytics firm. SA-BRC team offers a wide range of business intelligence services to multiple stakeholders such as Medical Device Manufacturers, Service Providers (Hospitals, Payers, etc.), Suppliers, Group Purchase Organizations, Distributors and all other individuals in the entire value chain of healthcare industry. Our research and consulting capabilities extend across several sub-domains within the sphere of Life Sciences such as Biotechnology, Healthcare IT, Medical Devices, Veterinary Sciences, Wellness Products and Pharmaceuticals.

Contact Us
John Whitmore
10685-B Hazelhurst Drive,
Suite 17411
Houston, Texas 77043,
United States
Phone: +1(832)-426-3701
Email: sales@sa-brc.com
Website: www.sa-brc.com

This release was published on openPR.